FYI
Neuren Pharmaceuticals (ASX:NEU)Simply Wall St Value Rating: ★★★★★★Overview: Neuren Pharmaceuticals is a company focused on the development of pharmaceutical products, with a market capitalization of approximately A$231.94 million.Operations: Pharmaceutical Products generated A$231.94 million in revenue, with a gross profit margin of 88.47%. The company's operating expenses were A$5.95 million.PE: 16.4xNeuren Pharmaceuticals, a lesser-known entity in the Australian market, recently showcased promising Phase 2 clinical trial results for NNZ-2591, targeting Pitt Hopkins syndrome—a condition with no approved treatments. This development could significantly enhance its market position. With revenue projected to increase by over 10% annually, and backed by insider confidence demonstrated through recent share purchases, Neuren's strategic moves suggest a potential upward trajectory in its valuation amidst small-cap peers.Fair Value $39.51
- Forums
- ASX - By Stock
- NEU
- Share Price
Share Price, page-10782
-
-
- There are more pages in this discussion • 1,289 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.14 |
Change
-0.130(0.85%) |
Mkt cap ! $1.935B |
Open | High | Low | Value | Volume |
$15.38 | $15.47 | $14.93 | $7.335M | 485.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7079 | $15.05 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.17 | 3189 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 7079 | 15.050 |
4 | 4738 | 15.040 |
1 | 1396 | 15.030 |
3 | 2653 | 15.020 |
2 | 2051 | 15.010 |
Price($) | Vol. | No. |
---|---|---|
15.170 | 3189 | 3 |
15.190 | 1441 | 2 |
15.200 | 1751 | 1 |
15.220 | 1751 | 1 |
15.250 | 1751 | 1 |
Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |